Clinical trial
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS…
NCT00148486 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00148486 |
|---|---|
| Title | A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) |
| Official title | A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | NS 2330 |
| Enrollment | 261 |
| Start date | Jun 1, 2003 |
| Primary completion | Mar 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Oct 29, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: